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Abstract
BACKGROUND: Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by 
erythrocytosis and commonly associated with the JAK2 V617F mutation. PV is a relatively rare disease with a 
prevalence rate of 22 per 100,000. Historically, hearing impairments were first described as a complication of PV 
in 1963, and it was stated that symptoms recovered after a phlebotomy. Occlusion and thrombosis of the feeding 
labyrinthine artery causing cochlear ischemia were thought to be the cause of such symptoms and complaints. 
CASE PRESENTATION: We are reporting a case of PV that was presented in our ENT outpatient clinic. The patient 
presented with a main complaint of sudden-onset bilateral tinnitus with one-sided hearing loss. The patient was 
treated medically with hydroxyurea, aspirin, and phlebotomy. On improvement of the hematological parameters, 
the patient noted an improvement in his hearing and it was confirmed with the finding on the repeated hearing 
assessment.
CONCLUSION: This case emphasizes the importance of otolaryngologists remaining vigilant and maintaining a high 
index of suspicion as PV can present with audiological symptoms. The early diagnosis and initiation of treatment can 
improve patients’ hearing and reduce the morbidity of such patients.
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Introduction
Polycythemia vera (PV) is a chronic 
myeloproliferative neoplasm (MPN) characterized by 
erythrocytosis and commonly associated with the JAK2 
V617F mutation. PV, essential thrombocythemia (ET), and 
primary myelofibrosis (PMF) belong to the same group of 
Philadelphia chromosome-negative MPNs [1]. PV is a 
relatively rare disease with a prevalence rate of 22 per 
100,000, and the incidence is higher in men than women. 
PV is typically diagnosed at 60–65 years of age [2]. The 
course of PV is variable as some patients are diagnosed 
only after routine blood work with few or no symptoms. In 
symptomatic patients, complaints are often non-specific; 
these symptoms include headaches, dizziness, blurring of 
vision, and pruritus. Severe complications are attributed to 
a high number of red blood cells and platelets that cause 
hyperviscosity and thrombotic events, such as cerebral 
infarctions, myocardial infarctions, and pulmonary 
embolisms [3]. Historically, hearing impairments were 
first described as a complication of PV in 1963, and it 
was stated that symptoms recovered after a phlebotomy. 
Occlusion and thrombosis of the feeding labyrinthine artery 
causing cochlear ischemia were thought to be the cause 
of such symptoms and complaints; however, tinnitus and 
hearing loss are rare initial presentations for patients with 
PV [4]. We are reporting a case of PV that was presented 
in our ENT outpatient clinic; the patient presented with a 
main complaint of sudden-onset bilateral tinnitus with one-
sided hearing loss.
Case Report
A 55-year-old gentleman presented with 
bilateral tinnitus and left-sided hearing loss that had 
been present for a month at our outpatient clinic. The 
symptoms occurred acutely and were not associated 
with otalgia, otorrhea, or dizziness. There was no 
previous history of acoustic trauma, otologic trauma, 
or drug intake. The patient denied any underlying 
chronic illnesses or comorbidities. His family history 
was negative for any hematological malignancies or 
hereditary hearing loss. On physical examination, 
both the external ear canal and tympanic membrane 
appeared normal. There was no facial nerve palsy or 
ophthalmoplegia. A nasal endoscopy was performed, 
nasopharynx and bilateral eustachian tube were found 
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to be normal. The tuning fork test showed a bilateral 
positive Rinne’s test with no lateralization on Weber’s 
test. Other systemic examinations were unremarkable.
Investigations showed a hemoglobin of 20.5 g/dL, 
a packed cell volume of 61%, platelet counts of 403 103/
uL, a total white blood cell count of 11.1 103/uL, and an 
erythrocyte sedimentation rate of 1 mm/hr. Pure tone 
audiometry showed normal hearing in the right ear and 
mild to moderately severe sensorineural hearing loss with 
downsloping over a high frequency with an average hearing 
level of 45 db (Figure 1). Tympanometry was performed 
and revealed Type A in both ears, which signifies normal 
middle ear pressure and function. Magnetic resonance 
imaging (MRI) of the brain and cerebellopontine angle 
was also performed which was reported as normal with 
no evidence of cerebellopontine angle mass.
The patient was subsequently referred to 
the department of hematology and oncology. Further 
investigation revealed erythrocytosis and thrombocytosis 
on peripheral blood smears and a decreased level 
of erythropoietin 3.0 mU/mL. The patient was tested 
positive for the JAK2 V6617F mutation. Based on two 
major criteria (hemoglobin 20.5 g/dL and the patient 
being JAK V6617F mutation positive) with one minor 
criteria (erythropoietin level of 3 mU/L), a diagnosis of 
PV was made. The patient was started on 500 mg of 
hydroxyurea twice daily, 100 mg of aspirin daily, and a 
phlebotomy was performed 3 times over a period of 6 
months. After 5 months of treatment, a review of the blood 
analysis was as follows: Hemoglobin was at 15.8 g/dL, 
hematocrit was 48%, and the platelet count was 305,000/
mcL. A repeated audiogram noted improvement in the 
left ear hearing at the higher frequency (Figure 2). The 
patient also reported a reduction in the intensity of the 
tinnitus. Tinnitus was also subjectively measured using 
the tinnitus handicap inventory score. On presentation, 
the score was 74/100; the second score was 68/100 
after 9 weeks of treatment when the hemoglobin level 
was 15.4 g/dL with a packed cell volume of 45%. The 
Figure 1: Pure tone audiometry on the first visit
Figure 2: Pure tone audiometry on post-treatment
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patient was followed up on regularly by our team and 
the hematology department. Ginkgo biloba at a 150 mg 
dosage twice daily was subsequently initiated, and the 
patient reported improvements in the intensity of tinnitus 
with a score of 58/100.
Discussion
The classification for hematopoietic neoplasm 
was recently revised in 2016. It recognizes MPN as a part 
of the myeloid malignancies. MPN includes PV, ET, and 
PMF [5]. PV is the most common among the group of MPN 
with an incidence of 0.01–2.61/100,000 and a prevalence 
of 0.49–46.88/100,000. The 5-year relative survival of PV 
was reported to be as high as 84.8% [6]. The diagnosis 
of PV is based on the revised World Health Organization 
criteria of three major or the first major and one minor 
criteria. The major criteria include (1) hemoglobin >16.5 g/
dL in men and >16.0 g/dL in women or hematocrit >49% in 
men and >48% women or increased red blood cell mass, 
(2) hypercellular bone marrow with trilineage growth, and 
(3) positive JAK2 mutation. The minor criterion is subnormal 
serum erythropoietin [5]. Common clinical symptoms range 
from mild non-specific complaints of pruritus, headache, 
weakness, and dizziness to severe complications of 
thrombosis and hemorrhaging. The reported incidence 
of thrombotic complications such as stroke, acute 
myocardial infarction, and pulmonary embolism in PV is 
between 13 and 60%. Hemorrhagic complications include 
epistaxis, gastrointestinal hemorrhage, or ecchymosis. 
ENT symptoms of tinnitus, hearing loss, vertigo, and facial 
weakness are also associated with the disease. Hearing 
loss and tinnitus are the most commonly reported otological 
symptoms [7], [8]. Outcomes of such symptoms vary with 
some patients experiencing significant improvement [9]. 
The pathophysiology of hearing loss in patients with PV 
is caused by an elevated hematocrit, increased red blood 
cell mass, high viscosity, and increased acute-phase 
reactants causing thrombosis in small vessels such as the 
labyrinthine artery. Both thrombosis and increased viscosity 
cause microvascular occlusion and were accepted as the 
primary cause of symptoms in PV. In a study by Dogan 
et al., patients with known PV were compared to healthy 
controls. Cochlear impairment was found to be significantly 
more common in PV group (p = 0.004) [10].
Kim et al. reported a case of PVwhich presented 
with symptoms of vertigo and on physical examination 
demonstrated gaze-evoked nystagmus. Similarly seen 
in our case, the findings and symptoms disappeared 
on normalizing of the blood parameters with repetitive 
phlebotomy and medical therapy of hydroxyurea 
and aspirin. The author also postulated that the 
pathophysiology of vertigo in PV could be explained 
by central vestibulopathy due to vascular insufficiency 
rather than peripheral vestibulopathy caused by inner 
ear vascular hyperviscosity [11].
However, hearing loss and tinnitus as initial 
reporting symptoms are rare, and no cases were found 
during a search of the PubMed archives. Before the 
conclusion of PV associated hearing loss in our patient, 
other organic causes of asymmetrical sensorineural 
hearing loss including acoustic neuroma were ruled 
out. PV is a chronic incurable disease with a reasonably 
good 5-year survival rate of 85%. However, a detailed 
and thorough workup is needed to reduce the rate of 
misdiagnosis due to the conflation of patients with ET 
and PV. Phlebotomy is the primary treatment for PV. It 
can effectively lower the hematocrit to <45% in males 
and <42% in females, which will effectively reduce the 
risk of developing PV complications of thrombosis [1].
A recently published guideline on the 
management of PV by Tefferi et al. proposed a risk 
stratification system in the treatment approach of 
patients with PV. The main objective in the treatment of 
both patients with PV and ET is prevention of potential 
thrombohemorrhagic complications. All patients with PV 
are advised for phlebotomy to maintain the hematocrit 
level below 45% and once or twice daily aspirin. In the 
very low-risk ET/PV group, patients might not require 
therapy while aspirin therapy is advised for those with 
low-risk disease. Cytoreductive therapy, however, is 
recommended only for high-risk ET and PV. The drug 
of choice for cytoreductive therapy, in both ET and 
PV, is hydroxyurea and second-line drugs of choice 
are interferon-α and busulfan [12]. For our patient, 
phlebotomy was performed 3 times during the initial 
6 months of therapy. The patient was also started on long-
term hydroxyurea therapy and aspirin for prophylaxis of 
thrombosis with phlebotomy performed periodically to 
keep hematocrit <45%. The duration of treatment will 
be determined by the hemato-oncology team based on 
close monitoring of symptoms and clinical response.
Ruxolitinib, a JAK 1 and JAK 2 selective 
inhibitor, is still being evaluated as a treatment option in 
view of the high rate of JAK2 mutations in patients with 
PV. At present, ruxolitinib has been approved by the 
US Food and Drug Administration for the treatment of 
patients with intermediate- and high-risk myelofibrosis or 
those with an inadequate response or are intolerant of 
hydroxyurea [11]. For our patient, after the phlebotomy 
was performed, the laboratory values of hemoglobin and 
hematocrit improved to normal limits. The patient noted 
that there were improvements in the tinnitus; however, his 
hearing did not recover to normal even though significant 
improvements were noted on the repeated pure tone 
audiometric tests post-treatment. A longer duration of 
follow-up is needed to determine the long-term outcome 
of PV on hearing loss and tinnitus in the patient.
Conclusion
We presented a case of a newly diagnosed 
PV patient with an unusual initial presentation of 
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tinnitus and hearing loss. This case emphasizes the 
importance of otolaryngologists remaining vigilant and 
maintaining a high index of suspicion as PV can present 
with audiological symptoms. The early diagnosis and 
initiation of treatment can improve patients’ hearing and 
reduce the morbidity of such patients.
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